Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

MLA

Choueiri, Toni K., et al. “Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 26, Sept. 2017, pp. 2993–3001. EBSCOhost, https://doi.org/10.1200/JCO.2017.72.2967.

APA

Choueiri, T. K., Plimack, E., Arkenau, H.-T., Jonasch, E., Heng, D. Y. C., Powles, T., Frigault, M. M., Clark, E. A., Handzel, A. A., Gardner, H., Morgan, S., Albiges, L., & Pal, S. K. (2017). Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(26), 2993–3001. https://doi.org/10.1200/JCO.2017.72.2967

Chicago

Choueiri, Toni K, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y C Heng, Thomas Powles, Melanie M Frigault, et al. 2017. “Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35 (26): 2993–3001. doi:10.1200/JCO.2017.72.2967.